REGN Regeneron Pharmaceuticals Earnings and EPS analysis

EPS in 2026 (TTM): $47.01

Last Report Period Date: Sep 30, 2026

As of November 2026, REGN's trailing twelve months (TTM) EPS stands at $47.01, according to the latest financial reports. In 2025, the company recorded an earnings per share (EPS) of $43.07, which represents an increase compared to its EPS of $40.9 in 2024. REGN reported an EPS of $19.16 for the quarterly report ending on Sep 30, 2026.

For 2025, Regeneron Pharmaceuticals's EPS was $43.07, an increase of 5.3% from $40.9 in 2024. For the quarter ending Sep 30, 2026, the EPS was $19.16, showing a 36% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of September 2026 is $47.01. In 2024, the annual EPS was $40.9, showing an increase of 10.4% from 2023.

Over the last 12 months, Regeneron Pharmaceuticals has registered an EPS growth of 36% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of 2.1% per year. Over the last 5 years, the company had an average EPS growth rate of 5.7%. When measured over a ten-year period, REGN's average EPS growth rate was 21.4%.